Adaptive Biotechnologies

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Adaptive Biotechnologies reports robust Q4 performance and eyes growth opportunities

Adaptive Biotechnologies delivered strong financial performance in Q4 2022 and full-year 2022, driven by growth in MRD and immune medicine segments, showcasing operational efficiency and revenue expansion.
While facing challenges such as paused T-Detect commercialization and revenue phasing complexities, the company is well-positioned to capitalize on opportunities like market acceptance of MRD and drug discovery partnerships.
With a positive revenue outlook for 2023, supported by strategic initiatives and a strong cash position, Adaptive Biotechnologies is poised for continued growth and market leadership in the biotechnology sector.

Adaptive Biotechnologies reports robust Q1 revenue and growth prospects

Adaptive Biotechnologies showcased strong revenue growth and operational improvements in Q1 2023.
The company is strategically positioned to capitalize on opportunities in MRD business and immune medicine segment.
Challenges include potential impacts from regulatory changes and the need for milestone achievements.
Overall, Adaptive Biotechnologies remains focused on growth, innovation, and expanding its market presence.

Adaptive Biotechnologies reports revenue growth and strategic partnerships in Q2

Adaptive Biotechnologies demonstrated solid revenue growth and margin improvement in Q2 2023, with a strategic outlook for future profitability.
Strong partnerships with Genentech and advocacy for MRD as a clinical endpoint position the company for continued success in the market.
Ongoing challenges in pricing and integration efforts are being addressed, while opportunities in drug discovery and AI-driven target discovery offer growth potential.

Adaptive Biotechnologies reports Q3 revenue growth amidst industry challenges

Adaptive Biotechnologies saw mixed performance with MRD growth and Immune Medicine decline.
Company's focus on MRD profitability and novel target identification shows strategic strength.
Facing challenges from industry softening and cost pressures but eyeing revenue growth opportunities.
Maintaining long-term target of $1,600 in 2027 while making progress towards profitability.

Adaptive Biotechnologies reports mixed Q4 results, focuses on MRD growth

Adaptive Biotechnologies navigated a transformative year in 2023, with a strong focus on MRD and Immune Medicine businesses. The company faces challenges in Immune Medicine revenue decline and achieving profitability. Strategic initiatives and partnerships position the company for growth and innovation in the biotechnology sector.

Adaptive Biotechnologies posts solid Q1 results, eyes breakeven targets

Adaptive Biotechnologies reported strong MRD revenue growth and aims to reduce operating expenses significantly in 2024. Despite a net loss, the company updated full-year guidance with a focus on achieving breakeven targets by 2025 and 2026. Opportunities lie in MRD segment expansion and immune medicine development.

Adaptive Biotechnologies excels in Q3 2024, eyes growth opportunities

Adaptive Biotechnologies delivered a robust performance in Q3 2024, marked by revenue growth, cost efficiencies, and strategic advancements in key segments.
While facing challenges in maintaining growth and profitability, the company's focus on operational excellence and innovation positions it well for future success.
With upcoming product launches and continued R&D efforts, Adaptive Biotechnologies is poised to capitalize on opportunities for market expansion and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.

Adaptive Biotechnologies: T-Cell Explorer In COVID-19 Battle Deserves A Premium

Adaptive Biotechnologies Corporation (ADPT) CEO Chad Robins on Q2 2020 Results - Earnings Call Transcript

Adaptive Biotechnologies’ revenue fell 5% to $21 million in the second quarter, and its net loss more than doubled to $33.

Industry slowdown hits Adaptive Biotech’s bottom line as COVID immune initiatives show progress

SEATTLE, Aug.  10, 2020  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2020.

Adaptive Biotechnologies Reports Second Quarter 2020 Financial Results

SEATTLE, Aug.  10, 2020  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming UBS Genomics 2.0 and Medtech Innovations Virtual Summit.

Adaptive Biotechnologies to Present at the UBS Genomics 2.0 and Medtech Innovations Summit

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia

Tailored for vaccine developers to accurately and reproducibly measure and track COVID-19 specific T-cell response in clinical trials

Adaptive Biotechnologies Launches immunoSEQ T-MAP COVID, First Molecular T Cell Monitoring Tool for SARS-CoV-2

Does this unusual biotech stock have what it takes to deliver market-beating gains?

Is Adaptive Biotechnologies a Buy?

Current tests are highly inaccurate, resulting in lengthy diagnostic journey Current tests are highly inaccurate, resulting in lengthy diagnostic journey

Adaptive Biotechnologies Launches National Clinical Trial to Develop Novel T-Cell Based Diagnostic for Lyme Disease

Topping-off ceremonies, in which workers place the last piece of structural steel for new building, have become run-of-the-mill over the past decade in Seattle’s South Lake Union neighborhood.

Adaptive Biotech pushes ahead with new Seattle HQ, showing strength of life sciences industry

Adaptive Biotechnologies (ADPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Adaptive Biotechnologies (ADPT) Upgraded to Buy: What Does It Mean for the Stock?

SEATTLE, July  15, 2020  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a public offering price of $40.00 per share, before deducting underwriting discounts and commissions (6,000,000 of which are being sold by Adaptive and 2,000,000 of which are being sold by a selling shareholder). In addition, Adaptive granted the underwriters a 30-day option to purchase up to 1,200,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering to Adaptive, before deducting the underwriting discounts and commissions, are expected to be $240 million. The offering is expected to close on July 20, 2020, subject to customary closing conditions.

Adaptive Biotechnologies Announces Pricing of Public Offering of Common Stock

Adaptive Biotechnologies announced Tuesday that it will sell 8 million shares of its common stock to help accelerate the company’s work.

Adaptive Biotechnologies will sell 8M shares to accelerate drug development

SEATTLE, July  14, 2020  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the commencement of a proposed underwritten public offering of 8,000,000 shares of its common stock (6,000,000 of which are being offered for sale by Adaptive and 2,000,000 of which are being offered for sale by a selling shareholder). In addition, Adaptive expects to grant the underwriters a 30-day option to purchase up to 1,200,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Adaptive Biotechnologies Announces Proposed Public Offering of Common Stock

Investors expect the company's technology platform to come in handy as the world corrals the coronavirus pandemic.

Here's Why Adaptive Biotechnologies Soared 61.7% in the First Half of 2020

SEATTLE, July  09, 2020  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter ended June 30, 2020 after market close on Monday, August 10, 2020. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Adaptive Biotechnologies to Report Second Quarter Financial Results on August 10, 2020

Adaptive Biotechnologies (ADPT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Adaptive Biotechnologies (ADPT) Stock Stands Out in a Strong Industry

Microsoft

Seattle-based Adaptive Biotechnologies and Microsoft have launched an open-access database called ImmuneCODE to catalog the many ways in which our immune systems fight off a coronavirus infection.

Adaptive Biotechnologies and Microsoft team up to track coronavirus-fighting cells

SEATTLE, June  08, 2020  (GLOBE NEWSWIRE) -- This release was previously disseminated on May 27, 2020 at 16:03 ET. The date and time details for the conferences have been updated. The complete and corrected release follows.

UPDATE – Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences

Amgen

CytoDyn Inc.

Gilead Sciences

Regeneron Pharmaceuticals

Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.

5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up

In the realm of diagnostic tests for COVID-19, there are two main approaches: PCR tests, which detect the presence of the live virus; and serology tests, which detect antibodies that indicate whether someone has recovered from the disease.

Inside the quest for a new COVID-19 test: Microsoft, Adaptive Biotech and the hidden power of immunity

Revenue skyrocketed in the first quarter. But so did Adaptive's spending.

What's Behind Adaptive Biotechnologies' Q1 Earnings Miss

Adaptive Biotechnologies Corporation (ADPT) CEO Chad Robins on Q1 2020 Results - Earnings Call Transcript

Adaptive Biotechnologies, which is working with Microsoft and Amgen to fight COVID-19 using its technology for sequencing the human immune system, reported a 65% increase in first quarter revenue, to nearly $21 million.

Adaptive Biotech revenue rises 65% to $21M, loss widens amid big COVID-19 immune partnerships

SEATTLE, May  12, 2020  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2020.

News for Adaptive Biotechnologies Stock (ADPT)